AI Reputation Analysis and Signal Evaluation – VEMLIDY (Gilead Sciences)

B
Reputation Level
Medical Devices, Pharma & Biotech
59.3 Avg Reputation

Based on 784 businesses audited.

Brand AI Reputation

Medical Devices, Pharma & Biotech Reputation: VEMLIDY (Gilead Sciences) (vemlidy.com)

https://vemlidy.com 📍 Industry: Medical Devices, Pharma & Biotech
62 Reputation / 100

VEMLIDY.com is a high-substance, compliant pharmaceutical site that is anchored by heavy regulatory requirements but weighed down by standard emotional marketing tropes. The BS score is kept low by the granular detail in the savings and safety sections, though the technical SEO and schema implementation are severely lacking. It successfully bridges the gap between patient emotion and clinical necessity without crossing into extreme hyperbole.

Info Density Power-words vs. Substance ratio.
22 73% Reputation
View evidence →
Semantic Coherence Homepage promise vs. Sub-page reality.
17 85% Reputation
View evidence →
Trust & Proof Verifiable evidence vs. Trust Theatre.
11 55% Reputation
View evidence →
Commodity Fingerprint Detection of industry clichés/templates.
7 47% Reputation
View evidence →
Identity & Authority Expert verifiability & Schema depth.
5 33% Reputation
View evidence →

Medical Devices, Pharma & Biotech Reputation: VEMLIDY (Gilead Sciences) (vemlidy.com)

Reputation: 62 / 100

The content perfectly aligns with the Pharma & Biotech category, specifically focusing on a prescription medication for chronic hepatitis B (HBV). The presence of mandatory Important Safety Information (ISI) and specific pharmacological details like tenofovir alafenamide 25 mg confirms this classification.

“The score of 62 is driven primarily by the high Information Density and Semantic Coherence pillars, which are strengthened by mandatory pharmaceutical disclosures. The score was penalized by the Identity and Authority pillar due to the complete lack of schema data and poor heading structure. Trust and Proof also contributed slightly to the BS score due to the reliance on anecdotal patient transcripts over direct clinical data summaries.”

Verified Analysis Date: May 26, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result